BR112013002877A2 - tratamento de doenças mitocondriais com naftoquinonas - Google Patents
tratamento de doenças mitocondriais com naftoquinonasInfo
- Publication number
- BR112013002877A2 BR112013002877A2 BR112013002877A BR112013002877A BR112013002877A2 BR 112013002877 A2 BR112013002877 A2 BR 112013002877A2 BR 112013002877 A BR112013002877 A BR 112013002877A BR 112013002877 A BR112013002877 A BR 112013002877A BR 112013002877 A2 BR112013002877 A2 BR 112013002877A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- mitochondrial diseases
- naphthoquinones
- treatment
- disclosed
- Prior art date
Links
- 208000012268 mitochondrial disease Diseases 0.000 title abstract 3
- 229930192627 Naphthoquinone Natural products 0.000 title abstract 2
- 150000002791 naphthoquinones Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- WLNBMPZUVDTASE-HXIISURNSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;sulfuric acid Chemical compound [O-]S([O-])(=O)=O.O=C[C@H]([NH3+])[C@@H](O)[C@H](O)[C@H](O)CO.O=C[C@H]([NH3+])[C@@H](O)[C@H](O)[C@H](O)CO WLNBMPZUVDTASE-HXIISURNSA-N 0.000 abstract 1
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 abstract 1
- 208000014644 Brain disease Diseases 0.000 abstract 1
- 208000032274 Encephalopathy Diseases 0.000 abstract 1
- 208000024412 Friedreich ataxia Diseases 0.000 abstract 1
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 abstract 1
- 208000006136 Leigh Disease Diseases 0.000 abstract 1
- 208000017507 Leigh syndrome Diseases 0.000 abstract 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 abstract 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40104410P | 2010-08-06 | 2010-08-06 | |
| PCT/US2011/046630 WO2012019029A2 (en) | 2010-08-06 | 2011-08-04 | Treatment of mitochondrial diseases with naphthoquinones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013002877A2 true BR112013002877A2 (pt) | 2016-05-31 |
Family
ID=45560075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013002877A BR112013002877A2 (pt) | 2010-08-06 | 2011-08-04 | tratamento de doenças mitocondriais com naftoquinonas |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20130345312A1 (https=) |
| EP (1) | EP2600857A4 (https=) |
| JP (2) | JP6045494B2 (https=) |
| AU (1) | AU2011285619B2 (https=) |
| BR (1) | BR112013002877A2 (https=) |
| CA (1) | CA2807507A1 (https=) |
| EA (1) | EA201300215A1 (https=) |
| MX (1) | MX2013001469A (https=) |
| SG (1) | SG187744A1 (https=) |
| WO (1) | WO2012019029A2 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| EP2471530B1 (en) | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| US9278085B2 (en) | 2006-02-22 | 2016-03-08 | Edison Pharmaceuticals, Inc. | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| WO2009061744A2 (en) | 2007-11-06 | 2009-05-14 | Edison Pharmaceuticals, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| EA023618B1 (ru) | 2008-01-08 | 2016-06-30 | Эдисон Фармасьютикалз, Инк. | Производные (гет)арил-п-хинона для лечения митохондриальных болезней |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| WO2009158348A1 (en) | 2008-06-25 | 2009-12-30 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| CA2741767C (en) | 2008-10-28 | 2017-09-12 | Ptc Therapeutics, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| PL2424495T3 (pl) | 2009-04-28 | 2018-06-29 | Bioelectron Technology Corporation | Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| HUE033757T2 (en) | 2012-07-12 | 2017-12-28 | Khondrion Ip B V | Chromanyl derivatives for treating mitochondrial disease |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| EP3626252A1 (en) | 2013-03-01 | 2020-03-25 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
| CN110339339A (zh) * | 2013-03-01 | 2019-10-18 | 康德生物医疗技术公司 | 治疗线粒体疾病的方法 |
| US10189830B2 (en) | 2013-03-15 | 2019-01-29 | Bioelectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US10047395B2 (en) | 2013-06-26 | 2018-08-14 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
| CA2936146A1 (en) * | 2014-01-06 | 2015-07-09 | Stealth Biotherapeutics Corp | Methods and compositions for preventing or treating dominant optic atrophy |
| AU2015364640B2 (en) | 2014-12-16 | 2020-08-13 | Ptc Therapeutics, Inc. | Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| ES3033538T3 (en) | 2015-10-08 | 2025-08-05 | Khondrion Ip B V | Novel compounds for treating mitochondrial disease |
| EP3390377B1 (en) | 2015-12-16 | 2026-03-25 | PTC Therapeutics, Inc. | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| KR102660473B1 (ko) | 2017-04-05 | 2024-04-24 | 콘드리온 아이피 비.브이. | 미토콘드리아 질환의 신규 치료 |
| CN110582480B (zh) * | 2017-04-21 | 2023-11-10 | 塔斯马尼亚大学 | 治疗化合物和方法 |
| WO2020028222A1 (en) * | 2018-07-29 | 2020-02-06 | Musc Foundation For Research Development | Compounds for the treatment of neurological or mitochondrial diseases |
| KR20210076956A (ko) | 2018-10-17 | 2021-06-24 | 피티씨 테라퓨틱스, 인크. | α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온 |
| CN113473977A (zh) | 2019-01-25 | 2021-10-01 | 巴塞罗那自治大学 | 用于治疗线粒体疾病用途的大麻二酚和/或其衍生物 |
| CN114746430B (zh) | 2019-10-04 | 2026-01-30 | 康德生物医疗有限公司 | 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物 |
| US12037350B2 (en) | 2020-04-03 | 2024-07-16 | Stealth Biotherapeutics Inc. | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia |
| IT202100006065A1 (it) * | 2021-03-15 | 2022-09-15 | Univ Degli Studi Padova | Composto per l’uso nel metodo di trattamento delle malattie mitocondriali da disfunzione dei complessi i, ii, iii della catena respiratoria |
| PE20240893A1 (es) | 2021-07-08 | 2024-04-24 | Ptc Therapeutics Inc | Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117326D0 (en) * | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| JP2003226639A (ja) * | 2002-01-31 | 2003-08-12 | Hisamitsu Pharmaceut Co Inc | 神経成長因子活性増強剤としてのビタミンｋ類を含む医薬組成物およびその使用 |
| US20040087527A1 (en) * | 2002-10-31 | 2004-05-06 | Day Brian J. | Methods for treatment of thiol-containing compound deficient conditions |
| EP2471530B1 (en) * | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| RU2318500C2 (ru) * | 2005-10-18 | 2008-03-10 | Общество С Ограниченной Ответственностью "Митотехнология" | Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели |
| US9278085B2 (en) * | 2006-02-22 | 2016-03-08 | Edison Pharmaceuticals, Inc. | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| KR20080047959A (ko) * | 2006-11-27 | 2008-05-30 | 주식회사 엠디바이오알파 | 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물 |
| WO2009111576A2 (en) * | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| EP2344142B1 (en) * | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| US20110172312A1 (en) * | 2009-12-31 | 2011-07-14 | Miller Guy M | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| EP2601168A4 (en) * | 2010-08-06 | 2013-12-04 | Ampere Life Sciences Inc | TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K |
| WO2012170773A1 (en) * | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
-
2011
- 2011-08-04 EA EA201300215A patent/EA201300215A1/ru unknown
- 2011-08-04 MX MX2013001469A patent/MX2013001469A/es unknown
- 2011-08-04 BR BR112013002877A patent/BR112013002877A2/pt not_active Application Discontinuation
- 2011-08-04 JP JP2013523342A patent/JP6045494B2/ja not_active Expired - Fee Related
- 2011-08-04 US US13/814,721 patent/US20130345312A1/en not_active Abandoned
- 2011-08-04 AU AU2011285619A patent/AU2011285619B2/en not_active Ceased
- 2011-08-04 WO PCT/US2011/046630 patent/WO2012019029A2/en not_active Ceased
- 2011-08-04 EP EP11815334.5A patent/EP2600857A4/en not_active Withdrawn
- 2011-08-04 SG SG2013009212A patent/SG187744A1/en unknown
- 2011-08-04 CA CA2807507A patent/CA2807507A1/en not_active Abandoned
-
2016
- 2016-01-04 JP JP2016000265A patent/JP2016041772A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2600857A2 (en) | 2013-06-12 |
| EA201300215A1 (ru) | 2013-07-30 |
| AU2011285619A1 (en) | 2013-03-07 |
| WO2012019029A3 (en) | 2013-08-15 |
| MX2013001469A (es) | 2013-05-14 |
| JP2016041772A (ja) | 2016-03-31 |
| CA2807507A1 (en) | 2012-02-09 |
| SG187744A1 (en) | 2013-03-28 |
| JP2013541502A (ja) | 2013-11-14 |
| EP2600857A4 (en) | 2014-06-11 |
| JP6045494B2 (ja) | 2016-12-14 |
| AU2011285619B2 (en) | 2016-12-01 |
| WO2012019029A2 (en) | 2012-02-09 |
| US20130345312A1 (en) | 2013-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013002877A2 (pt) | tratamento de doenças mitocondriais com naftoquinonas | |
| EP2601168A4 (en) | TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K | |
| CY1124292T1 (el) | Συνθεσεις για τροποποιηση της εκφρασης tau | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX391378B (es) | Derivados de fluoroalquil-, fluoroalcoxi-, fenoxi-, heteroariloxi-, alcoxi- y amina-1,4-benzoquinona para tratamiento de trastornos de estres oxidativo. | |
| MX392461B (es) | Moduladores de receptores estrogénicos | |
| EA201101668A1 (ru) | Редокс-активные терапевтические средства для лечения митохондриальных нарушений | |
| DOP2015000157A (es) | Lactamas fusionadas de arilo y heteroarilo | |
| DOP2016000017A (es) | Nuevos compuestos tricíclicos | |
| EA201001119A1 (ru) | Производные (гет)арил-п-хинона для лечения митохондриальных болезней | |
| ECSP14018375A (es) | 6-alquinilo piridinas como miméticos smac | |
| BR112016029612A2 (pt) | compostos de di-hidroisoquinolinona substituídos | |
| CL2015002556A1 (es) | Inhibidores de la ruta de quinurenina | |
| CU20150119A7 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| MX380829B (es) | Derivados de quinoxalina útiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa. | |
| MX378343B (es) | Derivados de 3-fenil-benzofuran-2-ona que contienen fosforo como estabilizantes. | |
| UY34593A (es) | Miméticos sintéticos de apelina para el tratamiento de falla cardiaca | |
| MX2014001717A (es) | Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas. | |
| CY1118118T1 (el) | Συνεργατικες θεραπειες cannabidiol μαζι με υποθερμια για νευρο-προστασια | |
| UY33883A (es) | Novedosos derivados heterocíclicos | |
| UY33199A (es) | 5-alquinil-pirimidinas. | |
| DOP2012000030A (es) | Polipéptidos del factor ix modificados y usos de los mismos | |
| UY34305A (es) | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar | |
| CY1117706T1 (el) | Παραγωγα οξαζολινης και ισοξαζολινης ως ρυθμιστες crac |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |